Shares of CELLECT BIOTECH/S (NASDAQ:APOP) have been given a consensus broker rating score of 1.00 (Strong Buy) from the one analysts that cover the company, Zacks Investment Research reports. One research analyst has rated the stock with a strong buy rating.

Brokers have set a 12 month consensus price target of $14.00 for the company and are expecting that the company will post ($0.28) earnings per share for the current quarter, according to Zacks. Zacks has also given CELLECT BIOTECH/S an industry rank of 95 out of 255 based on the ratings given to its competitors.

Several brokerages recently weighed in on APOP. HC Wainwright set a $14.00 price objective on CELLECT BIOTECH/S and gave the stock a “buy” rating in a research report on Friday, July 6th. ValuEngine upgraded CELLECT BIOTECH/S from a “sell” rating to a “hold” rating in a research report on Wednesday, June 6th. Finally, Zacks Investment Research upgraded CELLECT BIOTECH/S from a “hold” rating to a “buy” rating and set a $8.25 price objective for the company in a research report on Thursday, May 31st.

A hedge fund recently bought a new stake in CELLECT BIOTECH/S stock. Sabby Management LLC purchased a new position in shares of CELLECT BIOTECH/S (NASDAQ:APOP) during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 243,980 shares of the company’s stock, valued at approximately $1,557,000. CELLECT BIOTECH/S comprises approximately 0.2% of Sabby Management LLC’s holdings, making the stock its 23rd biggest position. Sabby Management LLC owned about 4.48% of CELLECT BIOTECH/S at the end of the most recent quarter. Hedge funds and other institutional investors own 3.70% of the company’s stock.

NASDAQ:APOP opened at $4.97 on Tuesday. CELLECT BIOTECH/S has a one year low of $4.40 and a one year high of $13.50.

CELLECT BIOTECH/S (NASDAQ:APOP) last issued its quarterly earnings data on Thursday, August 9th. The company reported ($0.26) earnings per share for the quarter, topping the consensus estimate of ($0.29) by $0.03. research analysts predict that CELLECT BIOTECH/S will post -0.98 EPS for the current fiscal year.


Cellect Biotechnology Ltd., a biotechnology company, focuses on developing technologies for the functional selection of stem cells in the field of regenerative medicine and stem cell therapies in Israel. It is developing the Apotainer selection kit, a shelf stem cell selection kit, based on its Powered by Cellect technology platform for allogeneic hematopoietic stem cell transplantation procedures for patients suffering from hematological malignancies.

Further Reading: Marijuana Stocks Future Looks Bright

Get a free copy of the Zacks research report on CELLECT BIOTECH/S (APOP)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for CELLECT BIOTECH/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CELLECT BIOTECH/S and related companies with's FREE daily email newsletter.